Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...
As of September 30, 2024, the Company had approximately $32.4 million in cash and cash equivalents compared with $48.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback